Jean-Luc Moreau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jean-Luc Moreau has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- François Jenck
Actelion Ltd., Gewerbestrasse 16, Allschwil, 4123, Switzerland
2 shared publications J.R. Martin
Pharma Division, Preclinical CNS Research, F. Hoffmann-La Roche Ltd, CH-4002 Basel, Switzerland
2 shared publicationsE P Bonetti
1 shared publicationF. Jenck
Pharma Division, Preclinical CNS Research, F. Hoffmann-La Roche Ltd, CH-4002 Basel, Switzerland
1 shared publicationG. Huber
Pharma Division, Preclinical CNS Research, F. Hoffmann‐La Roche Ltd., CH‐4002 Basel, Switzerland
1 shared publicationGerda Huber
Pharma Division, Preclinical CNS Research, F. Hoffmann-La Roche, PRPN, 72/141, CH-4070 Basel, Switzerland
1 shared publication
Latest Publications
- 1 December 1999
- Published by Elsevier in Brain Research Reviews
- Vol. 31 (1) , 65-82
Central adenosine A2A receptors: an overview
- 1 December 1999
- Published by Elsevier in Brain Research Reviews
- Vol. 31 (1) , 65-82
Central adenosine A2A receptors: an overview
- 1 August 1996
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 6 (3) , 169-175
5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats
- 1 August 1996
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 6 (3) , 169-175
5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats
- 1 January 1996
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 777 (1) , 293-296
β-APP Cognitive Function versus β-Amyloid-induced Cell Death
- 1 January 1996
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 777 (1) , 293-296
β-APP Cognitive Function versus β-Amyloid-induced Cell Death
- 1 December 1993
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 46 (4) , 905-910
Acute and chronic administration of buspirone fails to yield anxiolytic-like effects in a mouse operant punishment paradigm
- 1 December 1993
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 46 (4) , 905-910
Acute and chronic administration of buspirone fails to yield anxiolytic-like effects in a mouse operant punishment paradigm
- 1 January 1992
- Vol. 47, 379-94
Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders.
The classic benzodiazepines produce anxiolytic, anticonvulsant, sedative and myorelaxant effects at overlapping dose ranges. Efforts to reduce the sedative/myorelaxant component of this profile has a long history. Two rational approaches might theoretically lead to the desired drugs. One is based on the combination of partial (low efficacy) agonists of the benzodiazepine receptor with different receptor reserves in neurons subversing various functions. The other approach is based on the existence of GABAA-benzodiazepine receptor polymorphism and assumes that distinct receptor variants may be more prevalent on neurons involved in various CNS functions. Results are presented that were obtained with the partial agonist bretazenil and three other ligands in vitro as well as in vivo. Curves relating fractional receptor occupancy and various effects (potentiation of GABA-induced chloride flux, anticonvulsant, anticonflict and sedative effects) are fully consistent with the view that the particular profile of activity of bretazenil is the result of partial agonism. Comparison of fractional receptor occupancy required for the various effects of both full and partial agonists confirm earlier suggestions that receptor reserves for the individual effects differ with the same order. Clinical aspects of partial benzodiazepine receptor agonists are discussed on the basis of the preliminary information available to date.
- 1 January 1992
- Vol. 47, 379-94
Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders.
The classic benzodiazepines produce anxiolytic, anticonvulsant, sedative and myorelaxant effects at overlapping dose ranges. Efforts to reduce the sedative/myorelaxant component of this profile has a long history. Two rational approaches might theoretically lead to the desired drugs. One is based on the combination of partial (low efficacy) agonists of the benzodiazepine receptor with different receptor reserves in neurons subversing various functions. The other approach is based on the existence of GABAA-benzodiazepine receptor polymorphism and assumes that distinct receptor variants may be more prevalent on neurons involved in various CNS functions. Results are presented that were obtained with the partial agonist bretazenil and three other ligands in vitro as well as in vivo. Curves relating fractional receptor occupancy and various effects (potentiation of GABA-induced chloride flux, anticonvulsant, anticonflict and sedative effects) are fully consistent with the view that the particular profile of activity of bretazenil is the result of partial agonism. Comparison of fractional receptor occupancy required for the various effects of both full and partial agonists confirm earlier suggestions that receptor reserves for the individual effects differ with the same order. Clinical aspects of partial benzodiazepine receptor agonists are discussed on the basis of the preliminary information available to date.